María Celia
Miralles Alvarez
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (20)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain
HIV Medicine
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
Mortality in Perinatally HIV-infected Adolescents after Transition to Adult Care in Spain
Pediatric Infectious Disease Journal, Vol. 40, Núm. 4, pp. 347-350
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
Frontiers in Microbiology, Vol. 10, Núm. APR
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Cardiovascular risk factors and lifetime risk estimation in hiv-infected patients under antiretroviral treatment in Spain
HIV Clinical Trials, Vol. 16, Núm. 2, pp. 57-65
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792
2014
-
Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597
-
Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH
Nefrologia, Vol. 34, Núm. 6, pp. 768-788
2011
-
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C
Clinical Infectious Diseases, Vol. 53, Núm. 12, pp. 1291-1295
2009
-
Disorders of body fat distribution in HIV-1-infected patients
AIDS Reviews, Vol. 11, Núm. 3, pp. 126-134
2006
-
Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 2, pp. 96-117
2005
-
GEAM/SPNS recommendations for managing metabolic and morphologic alterations in patients with HIV infection
Nutrition and Metabolic Disorders in HIV Infection, Vol. 4, Núm. 2, pp. 617-698
2000
1999
-
A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients
AIDS, Vol. 13, Núm. 13, pp. 1727-1735